Abbas Sahebghadam Lotfi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Abbas Sahebghadam Lotfi has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
Masoud Soleimani
Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
4 shared publicationsMehdi Kamali
A Nanobiotechnology Research Center , Baqiyatallah University of Medical Sciences , Tehran , Iran
3 shared publicationsMorteza Abkar
Nanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz
3 shared publicationsNahid Davoodian
Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
3 shared publications- Amin Baghizadeh
Department of Biotechnology, Institute of Science and High Technology and Environmental Sciences, Graduate University of Advanced Technology, Kerman, Iran
2 shared publications - Aram Rezaei
Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
2 shared publications
Latest Publications
- Open Access
- 18 December 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Protective anti-fibrotic effect of liraglutide and Pirfenidone combination therapy on liver fibrosis in rats: effects on autophagy and NLRP3 inflammasome
Background: Liver fibrosis is a significant complication of chronic liver diseases. While Pirfenidone (PFD) and Liraglutide (LIR) have shown promise individually in treating fibrosis, their combined effect on autophagy and NLRP3 inflammasome pathways remains largely unexplored. Methods and results: This study investigated the protective effects of combined LIR and PFD therapy on autophagy and NLRP3 inflammasome, fifty male Wistar rats were divided into five groups: Sham, BDL, BDL + PFD (200 mg/kg), BDL + LIR (200 µg/kg), and BDL + PFD + LIR combination. Following 20 days of treatment, liver tissues were analyzed for histological and immunohistochemical (IHC) changes, biochemical parameters, and molecular markers of fibrosis, autophagy, and inflammasome activation. The combination therapy significantly reduced serum liver injury markers (ALT, AST, ALP), decreased ECM deposition, and improved histological parameters compared to monotherapy. Combined treatment effectively suppressed inflammatory markers (NF-κB, TNF-α) while increasing anti-inflammatory IL-10. Furthermore, the combination therapy modulated autophagy markers (Beclin 1), cathepsin B, and reduced NLRP3 inflammasome activation (NLRP3, Caspase 1, IL-1β, IL-18) more effectively than either drug alone. IHC staining of Ki-67 and HepPar-1 showed that combination therapy enhanced expression of proliferative and differentiation markers. Conclusions: PFD and LIR combination therapy demonstrates superior therapeutic efficacy in treating BDL-induced LF through enhanced liver regeneration through enhanced expression of proliferative and differentiation markers and modulation of autophagy and NLRP3 inflammasome pathways, indicating that the combination of PFD and LIR represents a promising therapeutic strategy for LF.
- 18 December 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Open AccessProtective anti-fibrotic effect of liraglutide and Pirfenidone combination therapy on liver fibrosis in rats: effects on autophagy and NLRP3 inflammasome
Background: Liver fibrosis is a significant complication of chronic liver diseases. While Pirfenidone (PFD) and Liraglutide (LIR) have shown promise individually in treating fibrosis, their combined effect on autophagy and NLRP3 inflammasome pathways remains largely unexplored. Methods and results: This study investigated the protective effects of combined LIR and PFD therapy on autophagy and NLRP3 inflammasome, fifty male Wistar rats were divided into five groups: Sham, BDL, BDL + PFD (200 mg/kg), BDL + LIR (200 µg/kg), and BDL + PFD + LIR combination. Following 20 days of treatment, liver tissues were analyzed for histological and immunohistochemical (IHC) changes, biochemical parameters, and molecular markers of fibrosis, autophagy, and inflammasome activation. The combination therapy significantly reduced serum liver injury markers (ALT, AST, ALP), decreased ECM deposition, and improved histological parameters compared to monotherapy. Combined treatment effectively suppressed inflammatory markers (NF-κB, TNF-α) while increasing anti-inflammatory IL-10. Furthermore, the combination therapy modulated autophagy markers (Beclin 1), cathepsin B, and reduced NLRP3 inflammasome activation (NLRP3, Caspase 1, IL-1β, IL-18) more effectively than either drug alone. IHC staining of Ki-67 and HepPar-1 showed that combination therapy enhanced expression of proliferative and differentiation markers. Conclusions: PFD and LIR combination therapy demonstrates superior therapeutic efficacy in treating BDL-induced LF through enhanced liver regeneration through enhanced expression of proliferative and differentiation markers and modulation of autophagy and NLRP3 inflammasome pathways, indicating that the combination of PFD and LIR represents a promising therapeutic strategy for LF.
- 16 November 2025
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 393 (1) , 103775
Targeting X-box–binding protein-1 by Decoy oligodeoxynucleotide modulates fibrogenic features of activated hepatic stellate cells
- 16 November 2025
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 393 (1) , 103775
Targeting X-box–binding protein-1 by Decoy oligodeoxynucleotide modulates fibrogenic features of activated hepatic stellate cells
- Open Access
- 18 March 2025
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 42, 101974
An association study of SERPINA1 gene polymorphisms with the risk of metabolic dysfunction-associated steatotic liver disease In an Iranian population: A preliminary case-control study
- 18 March 2025
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 42, 101974
Open AccessAn association study of SERPINA1 gene polymorphisms with the risk of metabolic dysfunction-associated steatotic liver disease In an Iranian population: A preliminary case-control study
- 1 February 2025
- Published by SAGE Publications in DNA and Cell Biology
- Vol. 44 (2) , 109-124
Pirfenidone Downregulates eIF6, P311, and TGF-β Expression and Improves Liver Fibrosis Induced by Bile Duct Ligation in Wistar Rats: Evidence for Liver Regeneration
Liver fibrosis (LF) is a clinical disorder characterized by inflammation and excessive accumulation of extracellular matrix (ECM). This study investigates the effects of the antifibrotic compound pirfenidone (PFD) on improving LF through histological changes and modulation of eukaryotic translation initiation factor 6 (eIF6), P311, and transforming growth factor beta (TGF-β) in rats with bile duct ligation (BDL)-induced LF. Rats received daily doses of PFD (200 and 500 mg/kg) for 4 weeks. The study encompassed biochemical, pathological, and immunohistochemical (IHC) analyses. mRNA levels of eIF6, P311, TGF-β, ECM deposition, hepatic stellate cell (HSC) activation, and inflammatory mediator genes were measured by RT-qPCR. Protein levels of eIF6, P311, and TGF-β were detected by western blotting. Compared with the BDL group, PFD dose-dependently reduced hydroxyproline content, liver index, biochemical parameters, fibrosis score, and fibrosis area. PFD also modulated BDL-induced hepatic inflammation, ECM accumulation, and HSC activation. IHC staining of Ki-67 and hepatocyte paraffin-1 revealed that PFD enhanced liver regeneration. The research confirmed that PFD gradually downregulated elevated eIF6, P311, and TGF-β levels in BDL-induced LF. These findings suggest that PFD could be a potential treatment for LF, as it may help attenuate fibrosis and enhance liver regeneration, possibly through the modulation of these specific markers.
- 1 February 2025
- Published by SAGE Publications in DNA and Cell Biology
- Vol. 44 (2) , 109-124
Pirfenidone Downregulates eIF6, P311, and TGF-β Expression and Improves Liver Fibrosis Induced by Bile Duct Ligation in Wistar Rats: Evidence for Liver Regeneration
Liver fibrosis (LF) is a clinical disorder characterized by inflammation and excessive accumulation of extracellular matrix (ECM). This study investigates the effects of the antifibrotic compound pirfenidone (PFD) on improving LF through histological changes and modulation of eukaryotic translation initiation factor 6 (eIF6), P311, and transforming growth factor beta (TGF-β) in rats with bile duct ligation (BDL)-induced LF. Rats received daily doses of PFD (200 and 500 mg/kg) for 4 weeks. The study encompassed biochemical, pathological, and immunohistochemical (IHC) analyses. mRNA levels of eIF6, P311, TGF-β, ECM deposition, hepatic stellate cell (HSC) activation, and inflammatory mediator genes were measured by RT-qPCR. Protein levels of eIF6, P311, and TGF-β were detected by western blotting. Compared with the BDL group, PFD dose-dependently reduced hydroxyproline content, liver index, biochemical parameters, fibrosis score, and fibrosis area. PFD also modulated BDL-induced hepatic inflammation, ECM accumulation, and HSC activation. IHC staining of Ki-67 and hepatocyte paraffin-1 revealed that PFD enhanced liver regeneration. The research confirmed that PFD gradually downregulated elevated eIF6, P311, and TGF-β levels in BDL-induced LF. These findings suggest that PFD could be a potential treatment for LF, as it may help attenuate fibrosis and enhance liver regeneration, possibly through the modulation of these specific markers.
- 18 October 2024
- Published by Springer Nature in Comparative Clinical Pathology
- Vol. 34 (1) , 9-20
The role of miR-30b-3p and miR-3162-3p in the progression and regression of hepatic fibrosis: insights from experimental and bioinformatics analyses
- 18 October 2024
- Published by Springer Nature in Comparative Clinical Pathology
- Vol. 34 (1) , 9-20
The role of miR-30b-3p and miR-3162-3p in the progression and regression of hepatic fibrosis: insights from experimental and bioinformatics analyses
- 15 May 2023
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 195 (8) , 4796-4817
Trimetazidine Preconditioning Potentiates the Effect of Mesenchymal Stem Cells Secretome on the Preservation of Rat Pancreatic Islet Survival and Function In Vitro
Islet transplantation offers improved glycemic control in individuals with type 1 diabetes mellitus. However, in vitro islet culture is associated with islet apoptosis and eventually will lose their functionality prior to transplantation. In this study, we examined the effects of mesenchymal stem cells (MSCs) secretome preconditioned with diazoxide (DZ) and trimetazidine (TMZ) on rat islet cells during pre-transplant culture. With and without preconditioned hAD-MSCs’ concentrated conditioned media (CCM) were added to the culture medium containing rat islets every 12 h for 24 and 48 h, after testing for selected cytokine concentrations (interleukin (IL)-4, IL-6, IL-13). Insulin content, glucose-stimulated insulin secretion, islet cell apoptosis, and mRNA expression of pro-apoptotic (BAX, BAK-1, and PUMA) and anti-apoptotic factors (BCL-2, BCL-xL, and XIAP) in rat islets were assessed after 24 and 48 h of culture. The protein level of IL-6 and IL-4 was significantly higher in TMZ-MSC-CM compared to MSC-non-CM. In rat isolated islets, normalized secreted insulin in the presence of 16.7 mM glucose was significantly higher in treated islet groups compared to control islets at both 24 and 48 h cultivation. Also, the percentage of apoptotic islet cells TMZ-MSC-CCM-treated islets was significantly lower compared to MSC-CM and MSC-CCM-treated islets in both 24 and 48 h cultivation. Consistent with the number of apoptotic cells, after 24 h culture, the expression of BCL-2 and BCL-xL genes in the control islets was lower than all treatment islet groups and in 48 h was lower than only TMZ-MSC-CM-treated islets. Also, the expression of the XIAP gene in control islets was significantly lower compared to the TMZ-MSC-CCM-treated islets at both at 24 and 48 h. In addition, mRNA level of the BAX gene in TMZ-MSC-CCM-treated islets was significantly lower compared to other groups at 48 h. Our findings revealed that TMZ proved to be more effective than DZ and could enhance the potential of hAD-MSCs-CM to improve the function and viability of islets prior to transplantation.
- 15 May 2023
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 195 (8) , 4796-4817
Trimetazidine Preconditioning Potentiates the Effect of Mesenchymal Stem Cells Secretome on the Preservation of Rat Pancreatic Islet Survival and Function In Vitro
Islet transplantation offers improved glycemic control in individuals with type 1 diabetes mellitus. However, in vitro islet culture is associated with islet apoptosis and eventually will lose their functionality prior to transplantation. In this study, we examined the effects of mesenchymal stem cells (MSCs) secretome preconditioned with diazoxide (DZ) and trimetazidine (TMZ) on rat islet cells during pre-transplant culture. With and without preconditioned hAD-MSCs’ concentrated conditioned media (CCM) were added to the culture medium containing rat islets every 12 h for 24 and 48 h, after testing for selected cytokine concentrations (interleukin (IL)-4, IL-6, IL-13). Insulin content, glucose-stimulated insulin secretion, islet cell apoptosis, and mRNA expression of pro-apoptotic (BAX, BAK-1, and PUMA) and anti-apoptotic factors (BCL-2, BCL-xL, and XIAP) in rat islets were assessed after 24 and 48 h of culture. The protein level of IL-6 and IL-4 was significantly higher in TMZ-MSC-CM compared to MSC-non-CM. In rat isolated islets, normalized secreted insulin in the presence of 16.7 mM glucose was significantly higher in treated islet groups compared to control islets at both 24 and 48 h cultivation. Also, the percentage of apoptotic islet cells TMZ-MSC-CCM-treated islets was significantly lower compared to MSC-CM and MSC-CCM-treated islets in both 24 and 48 h cultivation. Consistent with the number of apoptotic cells, after 24 h culture, the expression of BCL-2 and BCL-xL genes in the control islets was lower than all treatment islet groups and in 48 h was lower than only TMZ-MSC-CM-treated islets. Also, the expression of the XIAP gene in control islets was significantly lower compared to the TMZ-MSC-CCM-treated islets at both at 24 and 48 h. In addition, mRNA level of the BAX gene in TMZ-MSC-CCM-treated islets was significantly lower compared to other groups at 48 h. Our findings revealed that TMZ proved to be more effective than DZ and could enhance the potential of hAD-MSCs-CM to improve the function and viability of islets prior to transplantation.
- Open Access
- 29 August 2022
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 10, 943003
Immobilization of modular peptides on graphene cocktail for differentiation of human mesenchymal stem cells to hepatic-like cells
In this study, two novel biomimetic modular peptide motifs based on the alpha-2 subunit of type IV collagen (CO4A2) were designed and immobilized on a graphene platform to imitate integrin and heparan sulfate- (HS-) binding proteins. The in silico study was used to design 9-mer K[KGDRGD]AG and 10-mer KK[SGDRGD]AG for testing designed Integrin-Binding Peptide (dIBP) and HS-Binding Peptide (dHBP). The virtual docking technique was used to optimize the peptide motifs and their relevant receptors. Molecular dynamic (MD) simulation was used to evaluate the stability of peptide-receptor complexes. The effect of the platform on the differentiation of human mesenchymal stem cells (hMSCs) to hepatic-like cells (HLCs) was evaluated. After differentiation, some hepatic cells’ molecular markers such as albumin, AFP, CK-18, and CK-19 were successfully followed. Graphene-heparan sulfate binding peptide (G-HSBP) enhances the mature hepatic markers’ expression instead of control (p ≤ 0.05). The pathological study showed that the designed platform is safe, and no adverse effects were seen till 21 days after implantation.
- 29 August 2022
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 10, 943003
Open AccessImmobilization of modular peptides on graphene cocktail for differentiation of human mesenchymal stem cells to hepatic-like cells
In this study, two novel biomimetic modular peptide motifs based on the alpha-2 subunit of type IV collagen (CO4A2) were designed and immobilized on a graphene platform to imitate integrin and heparan sulfate- (HS-) binding proteins. The in silico study was used to design 9-mer K[KGDRGD]AG and 10-mer KK[SGDRGD]AG for testing designed Integrin-Binding Peptide (dIBP) and HS-Binding Peptide (dHBP). The virtual docking technique was used to optimize the peptide motifs and their relevant receptors. Molecular dynamic (MD) simulation was used to evaluate the stability of peptide-receptor complexes. The effect of the platform on the differentiation of human mesenchymal stem cells (hMSCs) to hepatic-like cells (HLCs) was evaluated. After differentiation, some hepatic cells’ molecular markers such as albumin, AFP, CK-18, and CK-19 were successfully followed. Graphene-heparan sulfate binding peptide (G-HSBP) enhances the mature hepatic markers’ expression instead of control (p ≤ 0.05). The pathological study showed that the designed platform is safe, and no adverse effects were seen till 21 days after implantation.
- 17 January 2022
- Published by Elsevier in Toxicology in Vitro
- Vol. 80, 105315
Hepatic stellate cell activation by TGFβ induces hedgehog signaling and endoplasmic reticulum stress simultaneously
- 17 January 2022
- Published by Elsevier in Toxicology in Vitro
- Vol. 80, 105315
Hepatic stellate cell activation by TGFβ induces hedgehog signaling and endoplasmic reticulum stress simultaneously
- 1 December 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 507 (1-4) , 15-21
Promoting hepatogenic differentiation of human mesenchymal stem cells using a novel laminin-containing gelatin cryogel scaffold
- 1 December 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 507 (1-4) , 15-21
Promoting hepatogenic differentiation of human mesenchymal stem cells using a novel laminin-containing gelatin cryogel scaffold
- 6 June 2018
- Published by Taylor & Francis in Artificial Cells, Nanomedicine, and Biotechnology
- Vol. 46 (sup2) , 727-736
The combinational effect of E6/E7 siRNA and anti-miR-182 on apoptosis induction in HPV16-positive cervical cells
In the present research, we assumed that reducing the amounts of E6 and E7 oncoproteins by a specific siRNA sequence and recovering p53 and RB proteins, along with the recovery of the FOXO1 protein by applying anti-miR-182, would increase apoptosis and reduce proliferation rate in cancer cells. The HPV16-positive CaSki cervical cancer cell line was used. 48 hours after transfection of siRNA for targeting E6 and E7 oncoproteins and anti-miR-182, expression of its cellular targets p53, p21 and FOXO1 was assessed by real-time PCR, western blot analysis and immunocytofluorescence staining. In all treatments, apoptosis rate and viability were evaluated using Annexin-V-FITC apoptosis detection kits and MTT assays, respectively. Among the designed siRNAs, E6-1 and E7-2 proved the most effective in reducing E6 and E7 expressions by increasing the apoptotic rates to 12.4% and 16%, respectively, after 48 hours. Also, using anti-miR-182 increased apoptotic rate to 12.7% 48 hours after transfection of cervical cancer cells. The combinational use of either E6-1 or E7-2 siRNAs with anti-miR-182 resulted in a rise in apoptosis to 19.3% and 26%, respectively, higher than those obtained from the individual application of either without anti-miR-182. The simultaneous use of siRNA E6-1 and siRNA E7-2 with cisplatin increased sensitivity to cisplatin and reduced the viability of the cancer cells as compared to the use of cisplatin alone. The simultaneous use of cisplatin and anti-miR-182 had no considerable effect on viability or apoptosis rate compared to cisplatin alone.
- 6 June 2018
- Published by Taylor & Francis in Artificial Cells, Nanomedicine, and Biotechnology
- Vol. 46 (sup2) , 727-736
The combinational effect of E6/E7 siRNA and anti-miR-182 on apoptosis induction in HPV16-positive cervical cells
In the present research, we assumed that reducing the amounts of E6 and E7 oncoproteins by a specific siRNA sequence and recovering p53 and RB proteins, along with the recovery of the FOXO1 protein by applying anti-miR-182, would increase apoptosis and reduce proliferation rate in cancer cells. The HPV16-positive CaSki cervical cancer cell line was used. 48 hours after transfection of siRNA for targeting E6 and E7 oncoproteins and anti-miR-182, expression of its cellular targets p53, p21 and FOXO1 was assessed by real-time PCR, western blot analysis and immunocytofluorescence staining. In all treatments, apoptosis rate and viability were evaluated using Annexin-V-FITC apoptosis detection kits and MTT assays, respectively. Among the designed siRNAs, E6-1 and E7-2 proved the most effective in reducing E6 and E7 expressions by increasing the apoptotic rates to 12.4% and 16%, respectively, after 48 hours. Also, using anti-miR-182 increased apoptotic rate to 12.7% 48 hours after transfection of cervical cancer cells. The combinational use of either E6-1 or E7-2 siRNAs with anti-miR-182 resulted in a rise in apoptosis to 19.3% and 26%, respectively, higher than those obtained from the individual application of either without anti-miR-182. The simultaneous use of siRNA E6-1 and siRNA E7-2 with cisplatin increased sensitivity to cisplatin and reduced the viability of the cancer cells as compared to the use of cisplatin alone. The simultaneous use of cisplatin and anti-miR-182 had no considerable effect on viability or apoptosis rate compared to cisplatin alone.